March 30, 2022 7:45am
It wouldn't be surprising to see this market rally thaw and cell and gene therapy sector slip
Pre-open indications: 10 SELLs into Strength and 1 pimp/pump/promote
RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Just the facts … I ask questions and note the indications of what could happen …
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are DOWN -0.20% (-70 points), S&P futures are DOWN -0.22% (-9 points) and NASDAQ futures are DOWN -0.31% (-47 points)
U.S. equity futures are down and slipping Wednesday after a rally in the previous session,
European stocks fell with an unknown outlook re any peace initiative or breakthrough in the war in Ukraine
Asia-Pacific stocks were mixed for same reasons
Henry’omics:
Saying it as it is, “The market’s now up almost 10% in the last 10 days, so we’ve had a pretty incredible rally in a very short time with not a whole lot of news change except that we actually have more rate hikes priced into the market,” “This has been a nice ride,” she added. “But I wouldn’t get too comfortable for the rest of this year, because I think we’re going to continue to see a lot of volatility.” Stephanie Lang, chief investment officer at Homrich Berg.” <CNBC>
RegMed Investors’ (RMi) closing bell: “cell and gene therapy equities are rising after being oversold and potential cease-fire initiative headlines.” … https://www.regmedinvestors.com/articles/12365
Ebb and flow –
· March – 11 negative and 10 positive closes
· February stats: 11 negative, 8 positive closes and 1 holiday
· January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes
Research Notes:
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... (VSTM, BCLI and ADVM) 34 total to date
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS/POTENTIALS or POSSIBILITIES
SELL into Strength:
- Alnylam Pharmaceuticals (ALNY) closed up =$5.09 with a positive +$0.26 or +0.16% pre-open indication.
- Beam Therapeutics (BEAM) closed up +$2.97 with a +$0.23 or +0.37% pre-open indication.
- Caribou Biosciences (CRBU) closed up +0.11 after Monday’s +$0.12 with a negative -$0.03 or -0.32% pre-open indication.
- CRISP Therapeutics (CRSP) closed up +$3.12 after Monday’s +$0.69 with a positive +$0.98 or +1.49% pre-open indication.
- Editas Medicine (EDIT) closed up +$1.68 with a negative -$0.02 or -0.10% pre-open indication.
- BioLife Solutions (BLFS) closed up +$1.49 after Monday’s +$0.30 after Friday’s -$1.116 with a negative -$0.00 or -0.01% pre-open indication.
- Fate Therapeutics (FATE) closed up +$3.94 with a negative -$0.34 or -0.81% pre-open indication.
- Intellia Therapeutics (NTLA) closed up +$3.15 with a positive +$0.27 or +0.35% pre-open indications.
- Ultragenyx (RARE) closed up +$3.52 with a $0.00 or 0% pre-open indication.
- Sage Therapeutics (SAGE) closed up +$1.59 with a $0.00 or 0% pre-open indication.
Pimp/Pump and Promote:
- Biostage (OTCQB: BSTG) closed down -$0.50 with 3,330 shares traded after Monday’s +$0.26 to $5.00 with 13,012 shares traded after Friday’s +$0.44 with 1,978 shares traded, Thursday’s flat with 34 shares traded, Wednesday with 4 shares traded and last Tuesday’s down -$0.17 with 202 shares traded. WHY BUY these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
The BOTTOM LINE: The sector rallied as the oversold got bought despite some skepticism and now comes the after matters – algorithmic “rules”.
I’m a firm believer in the flight of Icarus … since the cell and gene therapy equities have oscillated between gains and losses since the first of the year... a bigger “slip” is on the way!
That is why I say Sell into Strength.
Reiterating, “Resistance, sentiment algorithms and electronic trading numbing the share pricing as BOREDOM inhabits the sector.
Hold-on (to the railing) as a portfolio weather these volatile sessions is an ordinary practice.
Again, I reiterate, “I’m never totally wrong but, not always wholly right as there is no clear trend ….
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
